bluuebunny/crossref_metadata_2025_split huggingface dataset:
639-P: GIP Receptor Agonism Enhances Weight Loss from Either a Biased or an Unbiased GLP-1 Receptor Agonist in DIO Mice
Authors: COGHLAN MATTHEW P. , O’FARRELL LIBBEY , SHOWALTER AARON D. , WAINSCOTT DAVID B. , STUTSMAN CYNTHIA , CARDONA GUEMALLI , CABRERA OVER , ALSINA-FERNANDEZ JORGE , WILLARD FRANCIS S. , SLOOP KYLE , COSKUN TAMER 
Published: June 2021

GIP receptor (GIPR) agonism enhances the reduction of food intake and weight loss induced by GLP-1 receptor (GLP-1R) agonism. Recently, GLP-1R agonists have been described that exhibit biased agonism as determined using cells engineered to facilitate measuring the two canonical signaling pathways engaged upon binding the GLP-1R. Such “biased agonists” retain the ability to activate the G alpha S/cyclic AMP (cAMP) pathway to a similar magnitude as native GLP-1 but exhibit markedly weaker ability to induce receptor recruitment of beta-arrestin. The prototype biased GLP-1R agonist Exendin-Phe1 (Ex-Phe1) is reported to exhibit greater weight and glucose control in diet-induced obese (DIO) mice than its unbiased parent Exendin-4 (Ex4). Herein, we investigated whether the enhanced weight loss of Ex-Phe1 erodes the ability of GIPR agonism to further enhance the efficacy of GLP-1R agonism. The peptides were first characterized in vitro to validate the biased nature of Ex-Ph1. In cells expressing either the human or murine GLP-1R, Ex-Phe1 activated cAMP signaling to a similar magnitude as GLP-1 and Ex4 but with approximately 5-fold lower potency than Ex4. The maximum effect of Ex-Phe1 upon human or mouse GLP-1R recruitment of beta-arrestin was 20% compared with full efficacy for Ex4 relative to GLP-1. In this assay Ex-Phe1 was marginally less potent than Ex4. In a 14-day osmotic minipump DIO mice study, Ex4 and Ex-Phe1 each dose dependently reduced food intake and lowered body weight. Ex-Phe1 was 10-fold more potent than Ex4, and at the maximum dose, delivered superior weight loss. Combination treatment with d-Ala-GIP resulted in similar additional body weight loss to that achieved by either Ex-Phe1 or Ex4 alone by enhancing food intake reduction and increasing energy expenditure. D-Ala-GIP alone had no effect on body weight. These findings indicate that GIPR agonism enhances GLP-1R agonism mediated weight loss irrespective of the pathway bias nature of the latter.

Disclosure
M. P. Coghlan: Employee; Self; Eli Lilly and Company. K. Sloop: Employee; Self; Eli Lilly and Company. T. Coskun: Employee; Self; Eli Lilly and Company, Stock/Shareholder; Self; Eli Lilly and Company. L. O’farrell: None. A. D. Showalter: None. D. B. Wainscott: Employee; Self; Eli Lilly and Company, Employee; Spouse/Partner; Eli Lilly and Company, Stock/Shareholder; Self; Eli Lilly and Company, Stock/Shareholder; Spouse/Partner; Eli Lilly and Company. C. Stutsman: None. G. Cardona: Employee; Self; Eli Lilly and Company, Stock/Shareholder; Self; Eli Lilly and Company. O. Cabrera: None. J. Alsina-fernandez: None. F. S. Willard: Employee; Self; Eli Lilly and Company.

Funding
Eli Lilly and Company
64-LB: Glucose Control after Initiation of Flash Glucose Monitoring in Type 2 Diabetes Managed with Basal Insulin: A Retrospective Real-World Chart Review Study from the U.S.
Authors: CARLSON ANDERS L. , DANIEL TIMOTHY D. , DESANTIS ANDREA , JABBOUR SERGE , KARSLIOGLU-FRENCH ESRA , KRUGER DAVIDA F. , MILLER EDEN , OZER KEREM 
Published: June 2021

This retrospective, real-world, chart review study determined the effectiveness of the FreeStyle Libre® Flash Glucose Monitoring System on HbA1c when used by adults with type 2 diabetes (T2D) in a real-world setting between 3 months to 6 months after starting FreeStyle Libre. The study population included adults on a basal insulin regimen for at least 1 year, with HbA1c between 8.0 and 12.0% (64 to 108 mmol/mol), using FreeStyle Libre regularly for at least 3 months. Pregnant patients were excluded, as were patients on dialysis.
A total of 100 records from basal insulin using patients with T2D from 8 clinical sites in the US were included in this chart review. Mean HbA1c was 9.4±1.0% (79.2±11.1 mmol/mol), prior to FreeStyle Libre use, age was 56.0±10.3 years, BMI was 36.1±7.8 kg/m2 and average duration of insulin use 4.5±3.5 years (mean±SD); 96.0% of patients were on oral anti-diabetic medications in addition to basal insulin and 52.0% were male. HbA1c results were recorded between 90 to 194 days from the start of use of FreeStyle Libre, between December 2017 and March 2020. To minimise selection bias records were selected on a systematic basis.
After at least 3 months of using FreeStyle Libre in addition to their usual clinical care, HbA1c (primary outcome) was significantly reduced by 1.4±1.3% (mean±SD); p&lt;0.0001. Sub-group analysis by baseline HbA1c (&lt;9.0%, ≥9.0%) showed both groups significantly reduced HbA1c; with reductions of 0.8±0.7%, p&lt;0.0001 and 1.7±1.4%, p&lt;0.0001, respectively.
This real-world, chart review study concluded that people with T2D on basal insulin therapy, using FreeStyle Libre for between 3 to 6 months significantly reduced HbA1c.

Disclosure
A. L. Carlson: Board Member; Self; JDRF, Other Relationship; Self; Medtronic, Research Support; Self; Abbott Diabetes, Dexcom, Inc., Eli Lilly and Company, Novo Nordisk, Omnipod, Sanofi, UnitedHealth Group. T. D. Daniel: Advisory Panel; Self; Abbott Diabetes, Bayer Healthcare Pharmaceuticals Inc. A. Desantis: None. S. Jabbour: None. E. Karslioglu-french: None. D. F. Kruger: Advisory Panel; Self; Abbott Diabetes, Novo Nordisk, Sanofi US, Research Support; Self; Abbott Diabetes, Dexcom, Inc., Novo Nordisk, Speaker’s Bureau; Self; Dexcom, Inc., Eli Lilly and Company, Novo Nordisk, Stock/Shareholder; Self; Pendulum Therapeutics. E. Miller: Advisory Panel; Self; Abbott Diabetes, Boehringer Ingelheim Pharmaceuticals, Inc., Eli Lilly and Company, Novo Nordisk Inc., Research Support; Self; Pendulum Therapeutics, Research Support; Spouse/Partner; Abbott Diabetes. K. Ozer: Research Support; Self; Abbott Diabetes, AbbVie Inc., Eli Lilly and Company, Novo Nordisk, Senseonics, Speaker’s Bureau; Self; Boehringer Ingelheim Pharmaceuticals, Inc., Eli Lilly and Company, Novo Nordisk.

Funding
Abbott Diabetes Care
68-OR: Artificial Intelligence and Disparities in Pediatric Type 1 Diabetes Care: Predictive Model Performance Varies by Age and Sex
Authors: FERRO DIANA , WILLIAMS DAVID D. , PATTON SUSANA R. , MCDONOUGH RYAN , CLEMENTS MARK A. 
Published: June 2021

Background and Aim: We can use predictive models to intensify care among youth with type 1 diabetes (T1D) who are predicted to experience a rise in hemoglobin A1c (HbA1c), yet little is known about the impact of age and sex on the performance of machine learning-based models. We evaluated the performance of a model to predict 90-day change in HbA1c by sex and age.
Method: We applied supervised machine learning (random forest + natural language processing with 305 data features) to electronic health record data from May 2013 to December 2018 for 1725 youth aged 1-20 years with T1D seen at a Midwest US diabetes center with 11 sites. Eligible encounters included those with an HbA1c measurement &gt;70 days (median 106 days; IQR 94,132) after baseline, with resampling of youth who had multiple eligible encounters. We evaluated model performance characteristics (sensitivity, positive predicted values [PPV]) by age and sex to evaluate for disparities in performance.
Results: Median youth age was 14.3 years (IQR=10.9, 16.5), with 50.9% female and 17% non-Hispanic, non-white. Sensitivity and PPV of the model for predicting HbA1c rise of ≥0.3% were 12.4% and 47.2%, in the overall cohort, 13.8% and 51.4% in males, and 10.9% and 0.4% (p&lt;0.05) in females, respectively. Across age strata, senstivitity for males vs. females was 12.7% vs. 13% and 14.9% vs. 10.9% in youth 0-9 and 9-18 years old, respectively. PPV for males vs. females was 41% vs. 36% (p&lt;0.05), 54% vs. 43%, and 33.3% vs. 57.1% (p&lt;0.05) in youth 0-9 and 9-18 respectively.
Conclusions: Predictive models used in clinical practice should be examined for disparities in performance across groups. Our present predictive model exhibits disparities in performance characteristics by sex and age. Whether the model performs differently among groups defined by race, ethnicity, socioeconomic status, and treatment modalities remains to be determined; such disparities have the potential to exacerbate disparities in healthcare delivery.

Disclosure
D. Ferro: None. D. D. Williams: None. S. R. Patton: None. R. Mcdonough: None. M. A. Clements: Consultant; Self; Eli Lilly and Company, Employee; Self; Glooko, Inc., Research Support; Self; Abbott Diabetes, Dexcom, Inc.
686-P: The Association of British Clinical Diabetologists (ABCD) United Kingdom Nationwide Semaglutide Audit
Authors: CRABTREE THOMAS S.J. , BICKERTON ALEX , SENNIK DEVESH K. , ROHILLA ANURITA , SIVAPPRIYAN SIVA , BARNES DENNIS , CULL MELISSA L. , GALLEN IAN W. , ADAMSON KAREN , RYDER ROBERT E. 
Published: June 2021

In January 2019, the ABCD nationwide semaglutide audit was launched with the aim of providing real world evidence on semaglutide use in UK clinical practice.
Methods: Data were extracted from the ABCD audit tools and included providing they had sufficient follow-up data. Data were analysed in Stata SE 16. A planned sub-analysis of those switched from any other glucagon like peptide receptor-1 agonist (GLP1-RA) was performed.
Results: 1467 patient data sets were included with a mean±SD age 58.9 years ±11.1, weight 106.4kg ±23.2, BMI 36.8kg/m2 ±7.4, HbA1c 9.4% ±1.7 (79.1mmol/mol±18.6). This population is significantly different to the randomised control trial populations which had mean weight approx. 93kg and mean HbA1c approx. 8.2% (66mmol/mol). Median diabetes duration 10.6 years (IQR 5-14.7); 55.3% were male. The median follow-up period was 0.6years (IQR 0.4-0.8). In this cohort mean changes in HbA1c -1.2% (95% CI -1.1, -1.3) or -13.2mmol/mol (95% CI -11.8, -14.5) (P&lt;0.0001), weight of -4.6kg (95% CI -3.9, -5.2; P&lt;0.0001) and BMI -1.5kg/m2 (95% CI -1.3, -1.7, P&lt;0.0001) were noted from baseline across the population as a whole. 319 (21.75%) were switched from an alternative GLP1-agonist. Further changes in HbA1c of -0.8% (95% CI -0.6, -1.0) or -7.8mmol/mol (95% CI -5.4, -10.1)(P&lt;0.0001) and weight (-3.4kg; 95% CI -2.4, -4.3; P&lt;0.0001) were noted following the switch to semaglutide.
Conclusion: This early analysis demonstrates the differences between our real-world cohort and the more stringently controlled randomised control trial cohorts - in the UK semaglutide is being used in people with diabetes who are heavier and with higher HbA1c levels at baseline. Additional reductions in HbA1c and weight were observed in those switching from alternative GLP1-RAs.

Disclosure
T. S. J. Crabtree: Other Relationship; Self; Novo Nordisk, Sanofi. R. E. Ryder: Other Relationship; Self; Novo Nordisk. A. Bickerton: None. D. K. Sennik: Speaker’s Bureau; Self; AstraZeneca, Boehringer Ingelheim Pharmaceuticals, Inc. A. Rohilla: None. S. Sivappriyan: None. D. Barnes: None. M. L. Cull: None. I. W. Gallen: None. K. Adamson: None.

Funding
Association of British Clinical Diabetologists
701-P: Feasibility of an Investigational Extended Wear Infusion Set for Insulin Pump Therapy (IPT) in People with Type 1 Diabetes Mellitus
Authors: O’NEAL DAVID N. , VENKATESH NISHA , BROWN KATRIN , EKINCI ELIF I. , FOURLANOS SPIROS , KASTNER JASMIN R. , MACISAAC RICHARD , MUCHMORE DOUGLAS B. 
Published: June 2021

Background: Reliable insulin delivery is critical in the management of type 1 diabetes. Limitations of insulin pump therapy (IPT) are the maximum cannula life of three days, and a reported failure rate of 15-25% prior to this, which may impact glycemia and quality of life.
Objective: We aimed to determine the feasibility of a prototype cannula for an extended wear infusion set.
Materials and Methods: CapBio’s SteadiFlow technology (Capillary Biomedical, Irvine, CA, USA) consists of a cannula with a soft outer polymer reinforced by an internal metal coil to prevent kinking and three additional side ports to reduce the risk of cannula blockages. Adults with type 1 diabetes using IPT participated in a study with three study periods. For each period a new infusion set was inserted for an intended wear of 7 days. During Period 1 saline was infused via the investigational set through an additional insulin pump. During Periods 2 and 3 insulin lispro was delivered via the investigational set connected to the participant’s own insulin pump. Results are expressed as mean (SD).
Results: Twenty participants (Medtronic 640G [n=11]; 670G [n=3]; Tandem t-slim X2 [n=6]) with type 1 diabetes (age 44Y [14]; HbA1c 7.3% [0.6]/56mmol/mol [6]; female 50%) were studied. The 7-day survival rates of the prototype cannula set were 19/20 (95%) for period one and 36/41(88%) for periods two and three combined. No serious adverse events were reported. Mild infusion site reactions occurred in 7 participants. Hyperglycemia was reported as an adverse event in 7 participants resulting in premature cannula removal in 4 cases (occurring, respectively, on Days 1, 2, 5, and 6 during Weeks 2 or 3). Infusion site infection caused the 5th premature removal (on Day 3). Post-removal, no kinked cannulas were observed.
Conclusions: These study results confirm the feasibility of the extended-life investigational cannula. Larger, randomised studies are required to confirm these preliminary observations.

Disclosure
D. N. O’neal: Advisory Panel; Self; Abbott Diabetes, Medtronic, Sanofi, Research Support; Self; Dexcom, Inc., GlySens Incorporated, Medtronic, Pacific Diabetes Technologies. N. Venkatesh: None. K. Brown: None. E. I. Ekinci: None. S. Fourlanos: Advisory Panel; Self; Pfizer Foundation, Speaker’s Bureau; Self; AstraZeneca, Eli Lilly and Company. J. R. Kastner: None. R. Macisaac: Advisory Panel; Self; AstraZeneca, Bayer Healthcare Pharmaceuticals Inc., Novo Nordisk, Servier Laboratories, Speaker’s Bureau; Self; Boehringer Ingelheim International GmbH, Novo Nordisk. D. B. Muchmore: Consultant; Self; Capillary Biomedical, Inc., Diasome Pharmaceuticals, Inc., Zucara Therapeutics Inc., Stock/Shareholder; Self; Capillary Biomedical, Inc., Diasome Pharmaceuticals, Inc.
707-P: Use of Advanced Insulin Delivery Systems Is Not Associated with Fear of Hypoglycemia or Diabetes Treatment Satisfaction in Children and Their Caregivers with Type 1 Diabetes
Authors: ABDULHUSSEIN FATEMA , WONG JENISE C. 
Published: June 2021

Hypoglycemia occurs frequently in children with type 1 diabetes (T1D). However, the relationship between fear of hypoglycemia (FOH) and use of diabetes technology with different insulin delivery systems has not been well studied. Similarly, little is known about the relationship of diabetes treatment satisfaction with advances in diabetes technology in the pediatric population. Caregivers of children 6-17 years with T1D (n=104, 84% female caregivers, median T1D duration 5.3 years, mean GMI 7.5 ± 0.7%, 93% insulin pump users, 92% CGM users) using any insulin delivery system (8% MDI, 0.05% pump alone, 31% sensor augmented pump, 23% predictive low glucose suspend, 38% hybrid closed loop) completed the Hypoglycemia Fear Survey - Parent (HFS-P) and the Diabetes Treatment Satisfaction Questionnaire - Parent (DTSQ-P). Youth 13-17 years (n=35, 56% males) also completed the HFS - Child (HFS-C) and DTSQ - Child (DTSQ-C). Linear regression was used to look for associations between HFS and DTSQ scores and clinical factors, and paired t-tests were used to compare scores between caregivers and youth. Female caregivers had higher mean HFS Worry and Behavior scores than male caregivers (Worry 1.4 ± 0.18 vs. 0.88 ± 0.16, p=0.004; Behavior 4.9 ± 0.39 vs. 3.9 ± 0.3, p=0.008). Longer duration of diabetes, duration of pump use, and duration of CGM use were all associated with higher mean HFS-C Worry scores, but not with HFS-P Worry scores. The use of different insulin delivery systems was not associated with any HFS scores. Caregivers had a higher mean HFS Behavior score (4.8 ± 0.29) than youth (2.2 ± 0.078) (p &lt;0.0001). The only clinical factor that was associated with a lower DTSQ-P score was higher GMI (β-coefficient -0.22 ± 0.11, p=0.05). These data suggest that despite recent advancements in diabetes technology, FOH and diabetes treatment satisfaction still remain significant concerns and need to be addressed in clinical contexts.

Disclosure
F. Abdulhussein: None. J. C. Wong: Advisory Panel; Self; Provention Bio, Inc., Research Support; Self; Dexcom, Inc., Tandem Diabetes Care.
710-P: Real-World Evaluation of Glycemic Outcomes by Prior Therapy for People with Type 1 and Type 2 Diabetes Onboarding to Control-IQ Technology
Authors: MORBERG JOHN W. , SINGH HARSIMRAN , MCELWEE-MALLOY MOLLY , HABIF STEPHANIE , CONSTANTIN ALEXANDRA 
Published: June 2021

Previous research has demonstrated significantly improved glycemic outcomes in people with type 1 diabetes (PWT1D) and type 2 diabetes (PWT2D) who initiated use of Control-IQ technology by updating their existing pump software. This study examined glycemic outcomes by prior therapy (excluding software updaters) for PWT1D and PWT2D after they onboarded to Control-IQ technology. We performed retrospective analyses involving PWT1D and PWT2D from the US who purchased a new Tandem pump with Control-IQ technology and uploaded their pump data to t:connect® web application from Tandem Diabetes Care as of December 7, 2020. In all, 29,732 participants (94% T1D, 6% T2D) were included in the analysis. Median age of the sample was 40 years and majority had been using an insulin pump as prior therapy (66%) while 34% were transitioning from MDIs. After receiving their Tandem pump, prior pump users started using Control-IQ technology earlier (median days: T1D=16, T2D=16) than prior MDI users (T1D=21 days, T2D=23 days), mainly reflecting additional training provided to prior MDIs to onboard successfully to the new system. After 180 days of starting Control-IQ technology, for prior pump users with T1D, TIR was 74% (median, IQR 65-81%) and time below &lt;70mg/dl (TBR) was 1.2% (IQR 0.6-2.1%). For prior pump users with T2D, TIR was 76% (IQR 69-82%) and TBR was 0.5% (IQR 0.2-1.0%). For participants transitioning from MDI, Control-IQ technology resulted in TIR of 74% (IQR 64-83%) and 0.9% TBR (IQR 0.4-1.7%) for PWT1D and 74% TIR (IQR 63-84%) and 0.3% TBR (IQR 0.1-0.6%) for PWT2D. Irrespective of prior therapy, PWT1D changed their pump settings (e.g., basal rates, carbohydrate ratio) more frequently (median: 3) vs. PWT2D (median: 2). Using Control-IQ technology, both PWT1D and PWT2D (irrespective of prior therapy) achieved very similar TIR outcomes. However, T2D users showed lower rates of hypoglycemia (TBR) vs. their T1D counterparts.

Disclosure
J. W. Morberg: Employee; Self; Tandem Diabetes Care. H. Singh: Employee; Self; Tandem Diabetes Care. M. Mcelwee-malloy: Employee; Self; Tandem Diabetes Care. S. Habif: Employee; Self; Tandem Diabetes Care. A. Constantin: Employee; Self; Tandem Diabetes Care.
719-P: Caloric Intake, Appetite, and Body Composition Outcomes of Long-Term Intranasal Insulin (INI) Administration: A Substudy of the Memory Advancement by INI in Type 2 Diabetes (MemAID) Study
Authors: BECERRA LAURA APONTE , KHAN FAIZAN , NGO LONG H. , NOVAK VERA , MANTZOROS CHRISTOS ,   MEMAID COLLABORATORS, GAVRIELI A. , UPADHYAY J. 
Published: June 2021

Centrally administered insulin stimulates the reward system to reduce appetite in response to food intake in animal studies. Previous studies in humans have shown mixed results, suggesting INI may decrease appetite, body fat, and weight in non-obese and young males, but this hypothesis has not been tested in elderly with and without type 2 diabetes. This randomized, doubled blind trial consisted of 24 weeks of treatment with either 40 IU of INI (Novolin® R) or Placebo (sterile saline) once daily in elderly adults from MemAID. The primary outcome was the INI effect on food intake, and secondary outcomes included appetite, anthropometric measures, and body composition. In exploratory analyses, we tested the effect of INI on these outcomes when contrasting individuals by gender, BMI, and type 2 diabetes. Randomization included 121 participants, of which 89 (42 women, 53%; age 65±9 years; 46 INI, 52%; 38 diabetes, 43%) completed baseline and at least one intervention visit. Of those, 70 completed treatment (31 diabetes). There was no INI effect on caloric intake on any of the secondary outcomes. Sub-analyses comparing participants within the INI group also showed no differential effect on primary and secondary outcomes. We did not observe an overall INI effect on food intake, appetite, anthropometric measures, and body composition. However, whether insulin resistance may limit the effect of INI in participants without type 2 diabetes remains to be explored. Further research on the mechanisms underlying the potential effect of INI on appetite centrally is warranted (NCT02415556).

Disclosure
L. Aponte becerra: None. F. Khan: None. L. H. Ngo: Consultant; Self; Five Islands Consulting, Other Relationship; Self; Radiological Society of America. V. Novak: Advisory Panel; Spouse/Partner; Endonovo Therapeutics, Inc., Consultant; Spouse/Partner; Dysimmune Foundtation, Other Relationship; Spouse/Partner; Oxford University Press. Memaid collaborators (a. gavrieli, j. upadhyay): n/a. C. Mantzoros: Advisory Panel; Self; Amgen Inc., GENFIT, Intercept Pharmaceuticals, Inc., Novo Nordisk, Regeneron Pharmaceuticals Inc.

Funding
National Institute of Diabetes and Digestive and Kidney Diseases (1R01DK103902); U.S. Food and Drug Administration (IND107690); Novo Nordisk (ISS-001063), Medtronic (NERP15-0310); World Health Organization (UTN-U111-1175-1588)
723-P: Efficacy and Safety of Once-Daily Fixed-Ratio Coformulation of Degludec-Aspart plus Empa-Lina 25/5 FDC in Post-Discharge COVID-19 Pneumonitis T2DM Patients Treated with Dexamethasone during Inpatient Stay
Authors: BHATTACHARYYA SUPRATIK 
Published: June 2021

Background: Poor compliance is reported in hospitalised patients with T2D and COVID-19 who are discharged on Basal Bolus therapy (BBT). Hence, it is mandatory to explore novel therapeutic approaches.
Methods: A single-centred retrospective study aimed to evaluate the safety and efficacy of once daily IDegAsp plus Empagliflozin-Linagliptin FDC ± Metformin in T2DM patients who were non-compliant to BBT after being discharged from hospital post dexamethasone therapy.
Results: A retrospective chart analysis performed between 01 June 2020 and 31st December 2020 yielded a record of 67 patients (33 Female and 34 Male) meeting the eligibility criterion. Mean age of patients is 59.63 ± 9.89 years. Of the 67 patients, 59 (88.05%) were non-compliant with 3 bolus doses, 43 (64.18%) with 2 bolus doses and 21 (31.34%) with one bolus dose. The compliance was highest with once daily basal insulin in 64 (94.02%) of patients. It was further observed that the basal dose was sub-optimally up titrated to achieve fasting plasma glucose target and hence 100% failed to achieve their glycemic goals 14 days post discharge. The patients non-compliant with BBT regime and failing to achieve glycemic target post discharge, were switched to once daily IDegAsp along with Empa-Lina 25/5 FDC ± 1 gram of metformin. At the end of 13 weeks, the HbA1c reduced from 10.67±2.1% to 6.85±0.54% (p&lt;0.001) with FPG and PPG both declining from 212.72±52.01 to 118.68±15.54 mg/dL (p&lt;0.001) and 318.22±108.47 to 154.72±27.05 mg/dL (p&lt;0.001) respectively. The initial co-formulation dose requirement was 37.81±7.42 units which subsequently reduced to 17 ± 7.29 units, (p&lt;0.001).
Conclusion: Switching to once daily IDegAsp and Empa-Lina 25/5 FDC ± Metformin was an efficacious and safe alternative to Basal Bolus regimen post discharge for COVID-19 pneumonitis in T2DM patients treated with Dexamethasone during in-patient stay.

Disclosure
S. Bhattacharyya: None.